Treatment of small intestine bacterial overgrowth

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 4, 2005, Pages 217-222

  Di Stefano, M ^a   Miceli, E ^a   Missanelli, A ^a   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Diarrhoea; Hydrogen breast test; Intestinal gas production; Non absorbable antibiotics; Rifaximin; Small intestine bacterial overgrowth; Therapy

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BUSPIRONE; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CISAPRIDE; COTRIMOXAZOLE; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; LINCOMYCIN; METRONIDAZOLE; MINERAL; NEOMYCIN; NORFLOXACIN; OCTREOTIDE; PROBIOTIC AGENT; PROKINETIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN DERIVATIVE; RIFAXIMIN; SEROTONIN 4 AGONIST; SHORT CHAIN FATTY ACID; TEGASEROD; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VITAMIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL FLORA; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BLOATING; CALORIC INTAKE; CARDIOTOXICITY; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FLATULENCE; HUMAN; MALABSORPTION; NAUSEA; NONHUMAN; NUTRITIONAL REQUIREMENT; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; SMALL INTESTINE DISEASE; STEATORRHEA; SYMPTOMATOLOGY; VITAMIN INTAKE; WEIGHT REDUCTION;

ANTI-BACTERIAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL DISEASES; INTESTINE, SMALL; PROBIOTICS;

EID: 23744437044     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Donaldson RM Jr. Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med 1964; 270: 938-945.
2. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994; 106: 615-23.
3. King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology 1979; 76: 1035-1055.
4. Jones EA, Craigie A, Tavill AS, Franglen G, Rosenoer VM. Protein metabolism in the intestinal stagnant loop syndrome. Gut 1968;9:466-469.
5. Rutgeerts L, Mainguet P, Tytgat G, et al. Enterokinase in contaminated small-bowel syndrome. Digestion 1974; 10: 249-254.
6. Su J, Smith MB, Rerknimitr R, Morrow D. Small Intestine bacterial overgrowth presenting as protein losing enteropathy. Dig Dis Sci 1998; 43: 679-681.
7. Schjonsby H, Hofstad T. The uptake of vitamin B12 by the sediment of jejunal contents in patients with blind loop syndrome. Scand J Gastroenterol 1975; 10: 305-309.
8. Brandt LJ, Bernstein LJ, Wagle A. Production of vitamin B12 analogues in patients with small bowel bacterial overgrowth. Ann Intern Med 1977; 87: 546-551.
9. Di Stefano M, Veneto G, Malservisi S, Corazza GR. Small bowel bacterial overgrowth and metabolic osteopathy. Dig Dis Sci 2001; 46: 1077-1082.
10. Schiffer LM, Faloon WW, Chodos RB. Malabsorption syndrome associated with intestinal diverticulosis. Gastroenterology 1962; 42: 63-68.
11. Ament ME, Shimoda SS, Saunders DR, Rubin CE. Pathogenesis of steatorrhea in three cases of small intestinal stasis syndrome. Gastroenterology 1972; 63: 728-747.
12. Strocchi A, Levitt MD. Intestinal gas. In: Sleisenger MH, Fordtran JS. Gastrointestinal Disease. Saunders, Philadelphia. 1993: pp 1035-1042.
13. Riepe S, Goldstein J, Alpers DH. Effect of secreted bacteroides proteases on human intestinal brush border hydrolases. J Clin Invest 1980; 66: 314-322.
14. Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Gastroenterology 1990; 98: 302-309.
15. Camilleri M, Malagelada Jr, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis with intestinal pseudoobstruction. Gastroenterology 1989; 96: 704-712.
16. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995; 34: 265-269.
17. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461-1467.
18. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheen A, et al. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999; 29: 33-40.
19. Tack J, Coulie B, Wilmer A, Vos R, Janssens J. The 5-HT1A agonist buspirone induces a premature intestinal activity front in man. Gastroenterology 1997; 112: A834.
20. Di Stefano M, Vos R, Janssens J, Tack J. Effect of tegaserod on interdigestive and postprandial gastrointestinal motility. Gastroenterology 2003; 124(Suppl 1): S1148.
21. Banwell JG, Kistel LA, Giannella RA, Weber FL, Lieber A, Powell DE. Small intestine bacterial overgrowth syndrome. Gastroenterology 1981; 80: 834-845.
22. Sherwood WC, Goldstein F, Haurani FI, et al. Studies of the small intestinal bacterial flora and of intestinal absorption in pernicious anemia. Am J Dig Dis 1964; 9: 416-425.
23. Kahn IJ, Jeffries GJ, Sleisenger MH. Malabsorption in intestinal scleroderma: correction by antibiotics. N Engl J Med 1966; 274: 1339-1344.
24. Goldstein F, Wirts CW, Kramer S. The relationship of afferent loop stasis and bacterial flora to the production of postgastrectomy steatorrhea. Gastroenterology 1961; 40: 47-54.
25. Bjorneklett A, Fausa O, Midtvedt T. Bacterial overgrowth in jejunal and ileal disease. Scand J Gastroenterol 1983; 18: 289-298.
26. Bjorneklett A, Hoverstad T, Hovig T. Bacterial overgrowth. Scand J Gastroenterol 1985; 109: 123-132.
27. Toskes PP, Kumar A. Enteric bacterial flora and bacterial overgrowth syndrome. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Ed Feldman M, Sleisenger MH, Scharschmidt BF. Philadelphia: WB Saunders, 1998: pp 1523-1535.
28. Goldstein F, Wirts CW, Kowlessar OD. Diabetic diarrhea and steatorrhea. Ann Intern Med 1970; 72: 215-218.
29. Donaldson RM. Small bowel bacterial overgrowth. Adv Int Med 1970; 16: 191-212.
30. Gorbach SL, Tabaqchali S. Bacteria, bile and the small bowel. Gut 1969; 10: 963-972.
31. Joiner KA, Gorbach SL. Antimicrobial therapy of digestive diseases. Clin Gastroenterol 1979; 8: 3-35.
32. Elsborg L. Malabsorption in small intestinal diverticulosis treated with a low dosage sulphonamide-trimethoprim. Dan Med Bull 1977; 24: 33-35.
33. Tabaqchali S. The pathophysiological role of small intestinal bacterial flora. Scand J Gastroenterol 1970; Suppl 6: 139-163.
34. Bouhnik Y, Alain S, Attar A, et al. Bacterial population contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94: 1327-1331.
35. Vinci M, Gatto A, Gilgio A, et al. Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res 1984; 36: 92-99.
36. Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984; 6: 365-367.
37. DeLeo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979-981.
38. Alvisi V, D'Ambrosi A, Onofri W, Castellani M. Treatment of secretory diarrhoeas. A double-blind trial of the effectiveness of rifaximin (L/105) and neomycin. Clin Trials J 1984; 21: 215-223.
39. Palermo G, Di Gregorio P, Coffa G. Effectiveness of the L 105 compound in the treatment of acute diarrhoeal diseases. A short-term controlled study. Med Praxis 1984; 5: 147-152.
40. Eftimiadi C, DeLeo C, Schito GC. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exptl Clin Res 1984; 10: 691-696.
41. Gruttaduria G, LaBarbera F, Cutaia G, Salanitri G. Prevention of infection in colonic surgery by rifaximin. A controlled prospective randomized trial. Eur Rev Med Pharmacol Sci 1987; 9: 101-105.
42. Papi C, Ciacco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of uncomplicated diverticular disease of the colon. A multicenter trial. Ital J Gastroenterol 1992; 24: 452-456.
43. Corazza GR, Ventrucci M, Strocchi A, Sorge M, Pranzo L, Pezzilli R, Gasbarrini G. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988; 16: 312-316.
44. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556.
45. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 1999; 15: 47-52.
46. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal production and gas-related symptoms. Aliment Pharmacol Ther 2000; 14: 1001-1008.
47. Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117: 794-797.
48. Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1107-1112.
49. Ghoshal U, Ghoshal UC, Ranjan P, Naik SR, Ayyagari A. Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropic. BMC Gastroenterology 2003; 3: 9.
50. Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. acidophilus strains cereal) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires) 2002; 62: 159-163.
51. Di Stefano M, Miceli E, Missanelli A, Mazocchi S, Corazza GR. Absorbable vs non-absorbable antibiotics in the therapy of small intestine bacterial overgrowth in patients with blind loop syndrome. Aliment Pharmacol Ther 2005; 21: 985-992.